CONNECTA THERAPEUTICS RAISES €1.7 M TO DEVELOP NEW TREATMENT FOR FRAGILE X SYNDROME
Barcelona Inveready led the round of investment. CDTI and the biotechnology company’s founders also participated. Connecta Therapeutics was founded in Barcelona in 2019 as a spin-off of Prous Institute for Biomedical Research to develop new therapies for the central nervous system. Fragile X syndrome is an inherited genetic...
Continue reading